Date
18 November 2026
Op-ed: How pharmaceutical companies can turn medical innovation into equitable access
Significant progress has been made in making access to medicine a strategic priority, with 69% of late-stage pipeline candidates now covered by access plans – more than three times the proportion in 2018. However, Jayasree warns that these plans often lack sufficient commitments on affordability, reliable supply and reaching patients in the lowest-income countries, with particularly significant gaps in non-communicable diseases such as cancer, diabetes and obesity.Â
Jayasree argues that expanding access is both a public health responsibility and a commercial opportunity, as demand for medicines in emerging and developing markets continues to grow. She calls for companies to make access a more central part of their business models, supported by incentives such as coordinated procurement, advance purchase agreements and management targets linked to patient reach.
Drawing on the Foundation’s 20 years of benchmarking pharmaceutical companies, she also highlights the role of transparency and accountability in encouraging change. She concludes that no single approach will close the access gap: companies need to combine conventional commercial models with lower-margin and non-commercial approaches, voluntary licensing and technology transfer to ensure that medical innovation reaches the patients who need it most.Â
Â